Who is sponsoring NCT07314060?

NCT07314060 is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

What condition does NCT07314060 study?

NCT07314060 studies Generalized Pustular Psoriasis.

What drugs are being tested in NCT07314060?

Interventions: TQH2929 Injections, TQH2929 Placebo.

What is the status of NCT07314060?

NCT07314060 is currently RECRUITING.

Last reviewed 2026-03-20 · How we verify

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of TQH2929 Injection in Patients With Acute Exacerbations of Generalized Pustular Psoriasis

NCT07314060 Phase 2 RECRUITING

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection/placebo. The aim was to demonstrate the efficacy and safety of TQH2929 injection in patients with acute exacerbations of generalized pustular psoriasis, with a total of 36 subjects.

Details

Lead sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase	Phase 2
Status	RECRUITING
Enrolment	36
Start date	2026-03-19
Completion	2027-07

Conditions

Generalized Pustular Psoriasis

Interventions

TQH2929 Injections
TQH2929 Placebo

Primary outcomes

Percentage of patients with a score of 0 for the pustule subterm — 1 week
Percentage of patients with a Physician's Global Assessment of Generalized Pustular Psoriasis (GPPGA) pustular subitem of 0 (no visible pustules) at week 1 among all enrolled patients.

Countries

China